Thus, RCC treatment needs to be improved by inhibiting two major pathways in cell survival, i.e., Mitogen-activated protein kinases (MAPKs) and Mammalian target of Rapamycin (mTOR). This evidence concerns the gene MTOR and renal cell carcinoma.